TriangleEmavusertib (NCT07271667)
Emavusertib trial for Chronic Lymphocytic Leukemia (NCT07271667). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with chronic lymphocytic leukemia taking zanubrutinib. One group has residual disease after at least twelve months and a partial response. Another recently progressed on zanubrutinib, with standard options exhausted or unsuitable. Additional risk restrictions apply.
The idea: oral emavusertib twice daily accompanies zanubrutinib. They block IRAK4 and BTK signaling, respectively, pathways involved in cancer-cell survival. Researchers assess clearance of residual disease or tumor response by group. Initial results guide expansion.
This phase 2 study plans 108 patients. Curis sponsors the study; six US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.